- Home
- PTC vs TEVA Comparison
PTC vs TEVA Comparison
Compare PTC & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTC
- TEVA
- Stock Information
- Founded
- PTC 1985
- TEVA 1901
- Country
- PTC United States
- TEVA Israel
- Employees
- PTC N/A
- TEVA N/A
- Industry
- PTC Computer Software: Prepackaged Software
- TEVA Biotechnology: Pharmaceutical Preparations
- Sector
- PTC Technology
- TEVA Health Care
- Exchange
- PTC Nasdaq
- TEVA Nasdaq
- Market Cap
- PTC 20.2B
- TEVA 18.8B
- IPO Year
- PTC 1989
- TEVA N/A
- Fundamental
- Price
- PTC $215.05
- TEVA $18.47
- Analyst Decision
- PTC Buy
- TEVA Strong Buy
- Analyst Count
- PTC 13
- TEVA 7
- Target Price
- PTC $209.77
- TEVA $24.71
- AVG Volume (30 Days)
- PTC 975.7K
- TEVA 13.4M
- Earning Date
- PTC 07-30-2025
- TEVA 07-30-2025
- Dividend Yield
- PTC N/A
- TEVA N/A
- EPS Growth
- PTC 73.27
- TEVA N/A
- EPS
- PTC 4.25
- TEVA N/A
- Revenue
- PTC $2,471,978,000.00
- TEVA $16,628,000,000.00
- Revenue This Year
- PTC $9.94
- TEVA $5.19
- Revenue Next Year
- PTC $9.02
- TEVA $0.16
- P/E Ratio
- PTC $50.62
- TEVA N/A
- Revenue Growth
- PTC 11.42
- TEVA 2.08
- 52 Week Low
- PTC $133.38
- TEVA $12.47
- 52 Week High
- PTC $219.69
- TEVA $22.80
- Technical
- Relative Strength Index (RSI)
- PTC 65.40
- TEVA 66.52
- Support Level
- PTC $208.17
- TEVA $17.33
- Resistance Level
- PTC $208.99
- TEVA $18.28
- Average True Range (ATR)
- PTC 4.28
- TEVA 0.48
- MACD
- PTC -0.53
- TEVA 0.24
- Stochastic Oscillator
- PTC 85.80
- TEVA 82.25
About PTC PTC Inc.
PTC offers high-end computer-assisted design (Creo) and product lifecycle management (Windchill) software as well as Internet of Things and AR industrial solutions. Founded in 1985, PTC has 28,000 customers, with revenue stemming mostly from North America and Europe.
About TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.